News

HDA Media And Political Bulletin – 17 December 2015

Health devolution for London needs Pharmacy at an early stage

Pharmacy Business, 16 December 2015

Pharmacy Voice’s chief executive, Rob Darracott, welcomed the announcement of the devolution of NHS powers to local councils in London, launched with 5 pilot schemes. These local schemes are expected to better integrate health and social care budgets. Rob Darracott added that pharmacy had an important role to play in the process, in the same way it had led the implementation of the national flu vaccine service.

 

ABPI welcomes the publication of a new report by IMS Health on ‘The Impact of Biosimilar Competition’

ABPI, 16 December 2015

ABPI welcomes the publication of a new report by IMS Health on ‘The Impact of Biosimilar Competition’, requested by the European Commission. The report’s key findings should inform healthcare policy developments in the UK, particularly ensuring a competitive market to drive cost savings.

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Health devolution for London needs Pharmacy at an early stage

Pharmacy Business, 16 December 2015

Rob Darracott, the chief executive of Pharmacy Voice, has welcomed the government’s health devolution for London agreement but cautioned that “hard work is needed to ensure community pharmacy is included at an early stage.”

Optimism has surrounded the deal, signed by the Chancellor George Osborne, which will transfer power over health and care services from Whitehall to local leaders in London.

The deal was signed with London’s Clinical Commissioning Groups, local authorities, the Greater London Authority as well as NHS England, Health Education England, NHS Improvement and Public Health England.

 

Five pilot schemes have been launched in Haringey, Barking and Dagenham, Havering and Redbridge, North Central London and Lewisham and Hackney. The latter will strive for an integration of health and social care budgets, with a heavy accent placed on prevention.

“(This) agreement is another crucial step in our devolution revolution and is the start of us handing over valuable healthcare power to local leaders in London,” Osborne said.

“This deal means that not only will the people of London have more control over decisions that affect their lives, it will also lead to better, more joined up health care in the capital for Londoners.”

Darracott (pictured) said: “It is a positive move that London is being offered the opportunity to transform the way that social and health care services are delivered through the devolution pilots announced by the Government this.

“Pharmacies in London have led the charge with the flu vaccination programme laying the groundwork for the national service. More specifically I have seen first-hand the fantastic work delivered by community pharmacy in Hackney around prevention and it is fantastic that these teams are actively involved in the Hackney pilot.

“The four further pilots also look to have good opportunities for community pharmacy. As always, hard work is needed to ensure community pharmacy is included at an early stage in planning and delivering the pilots.

“Pharmacy Voice will look to support local teams demonstrating the huge potential that the 1,885 community pharmacies in London can offer to improve health outcomes.”

 

ABPI welcomes the publication of a new report by IMS Health on ‘The Impact of Biosimilar Competition’

ABPI, 16 December 2015

Alongside our colleagues at the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generics Association (EGA) and EuropaBio, we welcome the publication of a new report by IMS Health on ‘The Impact of Biosimilar Competition’.

​​​​The publication was developed at the request of the European Commission and provides an assessment of the effects of biosimilar competition on price and volume across Europe, drawing on data from 2014. It can be found at the website of the European Commission.

Its key findings are as follows:

  • Sustainable competition in the biological medicines market underpins the potential for healthcare savings and increased access;
  • Uptake of biosimilar medicines varies widely between countries and across therapeutic areas, driven by national considerations such as the types of products available in each medicine class;
  • There is a weak correlation between biosimilars market share and price erosion of biological medicines;
  • There is potential for significant savings associated with increased competition, despite biosimilar medicines not being able to offer the same percentage price reductions as generic medicines, due to the challenges and cost of development.

The findings of the report will help inform policy development in the UK as the market for off-patent biological medicines, including reference products and biosimilar medicines, continues to grow and evolve.

As the report confirms, it is important that policies developed in the UK support competition and a sustainable biological medicines market. Savings made through successfully establishing a competitive marketplace should be reinvested to support greater and earlier patient access to biological medicines, where the UK currently lags behind Europe in several therapeutic areas such as rheumatoid arthritis.

Policies developed should take the specific conditions of the biological medicines market into consideration. Policies should also ensure that prescribing decisions continue to be made firstly by the responsible clinician in consultation with their patient and secondly on the basis of the overall value proposition offered by an individual medicine.

A further report summarising discussions at a workshop on Access to and Uptake of Biosimilar Medicinal Products which took place on 6 October 2015, has been published alongside the IMS report. This can be found at the website of the European Commission.​

HDA Media And Political Bulletin – 17 December 2015

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?